GTX INC License Agreements

24 Contracts & Agreements
Recent Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
Amendment #2 to Amended and Restated License Agreement between Oncternal Therapeutics, Inc. and the Regents of the University of California, dated May 15, 2019
License Agreements
GTX INC
Biotechnology
2020
Amended and Restated License Agreement between Oncternal Oncology, Inc. and The Regents of the University of California dated August 6, 2024
License Agreements
GTX INC
Biotechnology
CA
2024
Second Amendment to the UTRF License Agreement dated March 4, 2024
License Agreements
GTX INC
Biotechnology
2024
Amendment #4 to the Amended and Restated License Agreement between Oncternal Therapeutics, Inc. and UC San Diego dated August 31, 2018
License Agreements
GTX INC
Biotechnology
2024
First Amendment to the Amended and Restated License Agreement Between the University of Tennessee Research Foundation and the Registrant dated August 22, 2022
License Agreements
GTX INC
Biotechnology
2022
Amended and Restated License Agreement between the University of Tennessee Research Foundation and the Registrant Oncternal Therapeutics, Inc. dated March 9, 2022
License Agreements
GTX INC
Biotechnology
2022
Amendment #3 to Amended and Restated License Agreement between Oncternal Therapeutics, Inc. and the Regents of the University of California, dated February 5, 2021
License Agreements
GTX INC
Biotechnology
2021
Amendment No. 1 to Commercial License Agreement between Selexis SA and Oncternal Therapeutics, Inc., dated February 7, 2020
License Agreements
GTX INC
Biotechnology
2020
Amendment #1 to Amended and Restated License Agreement between Oncternal Therapeutics, Inc. and the Regents of the University of California, dated March 25, 2019
License Agreements
GTX INC
Biotechnology
2019
Amended and Restated License Agreement between Oncternal Therapeutics, Inc. and The Regents of the University of California, dated August 31, 2018
License Agreements
GTX INC
Biotechnology
CA
2019
License Agreement between Oncternal Therapeutics, Inc. and Velos Biopharma Holdings, LLC, dated February 6, 2018
License Agreements
GTX INC
Biotechnology
DE
2019
Amendment to Exclusive License Agreement between Georgetown University and Oncternal Therapeutics, Inc., dated March 17, 2016
License Agreements
GTX INC
Biotechnology
2019
Exclusive License Agreement between Georgetown University and Oncternal Therapeutics, Inc., dated March 26, 2014
License Agreements
GTX INC
Biotechnology
DE
2019
Commercial License Agreement between Selexis SA (predecessor to Oncternal Therapeutics, Inc.) and ROAR Therapeutics, LLC, dated May 19, 2014
License Agreements
GTX INC
Biotechnology
2019
Amendment #4 to the License Agreement, as amended, dated October 23, 2018, between the Registrant and University of Tennessee Research Foundation
License Agreements
GTX INC
Biotechnology
2019
Amendment #3 to the License Agreement, as amended, dated April 6, 2017, between the Registrant and University of Tennessee Research Foundation
License Agreements
GTX INC
Biotechnology
2019
Amendment #2 to the License Agreement, as amended, dated August 12, 2016, between the Registrant and University of Tennessee Research Foundation
License Agreements
GTX INC
Biotechnology
2019
Amendment #1 to the License Agreement, dated November 12, 2015, between the Registrant and University of Tennessee Research Foundation
License Agreements
GTX INC
Biotechnology
2019
License Agreement, effective March 1, 2015, between the Registrant and University of Tennessee Research Foundation
License Agreements
GTX INC
Biotechnology
2019
EX-10.41 Amended and Restated License Agreement
License Agreements
GTX INC
Biotechnology
TN
2007
EX-10.40 Consolidated, Amended, License Agreement
License Agreements
GTX INC
Biotechnology
TN
2007
Ex-10.15 Amended License & Supply Agreement
License Agreements
GTX INC
Biotechnology
2007
Ex-10.36 Partial Assignment of License & Supply Agreement
License Agreements
GTX INC
Biotechnology
2006
Ex-10.2 Amended and Restated License Supply Agreement
License Agreements
GTX INC
Biotechnology
2005